4356 J ournal of Medicinal Chemistry, 1996, Vol. 39, No. 22
Communications to the Editor
(12) Gold, P. W.; Loriaux, D. L.; Roy, A.; Kling, M. A.; Calabrese, J .
R.; Kellner, C. H.; Nieman, L. K.; Post, R. M.; Pickar, D.;
Gallucci, W.; Avgerinos, P.; Paul, S.; Oldfield, E. H.; Cutler, G.
B. J .; Chrousos, G. P. Responses to corticotropin-releasing
hormone in the hypercortisolism of depression and Cushing’s
disease. N. Engl. J . Med. 1986, 314, 1329-1334.
In summary, potent CRF receptor antagonists in the
range of 50 nM (5b) were identified by preparing over
350 analogs of an initial lead (5u ) (Ki ) 2100 nM) on a
multimilligram scale using rapid microscale synthesis
(RMS). RMS provides an alternative and convenient
method to robotics driven solid phase synthesis for
preparing up to several hundred analogs of a biologically
active molecule in a relatively short period of time.
(13) Koob, G. F. Stress, corticotropin-releasing factor and behavior.
Perspect. Behav. Med. 1985, 2, 39-52.
(14) Owens, M. J .; Nemeroff, C. B. Physiology and pharmacology of
corticotropin-releasing factor. Pharmacol. Rev. 1991, 43, 425-
473.
(15) Dunn, A. J .; Berridge, C. W. Physiological and behavioral
responses to corticotropin-releasing factor administration: is
CRF a mediator of anxiety of stress responses? Brain Res. Rev.
1990, 15, 71-100.
(16) De Souza, E. B.; Nemeroff, C. B. Corticotropin-releasing factor:
Basic and clinical studies of a neuropeptide; CRC Press, Inc.:
Boca Raton, FL, 1990.
(17) Further details on the instrument are available from the
manufacturer. The modifications to the PrepStation are now
commercially available from the manufacturer.
Ackn owledgm en t. We wish to thank W. A. Schmidt,
P. Snipes, M. P. Scott, and K. Fogelman from Hewlett-
Packard Co. for their technical support. This work was
supported in part by a grant funded through the Small
Business Innovative Research (SBIR) program at NIH,
Identification Number 1R43 NS334879.
(18) Frisbee, A. R. N.; Kramer, G. W.; Fuchs, P. L. Robotic orchestra-
tion of organic reactions: Yield optimization via an automated
system with operator-specified reaction sequences. J . Am. Chem.
Soc. 1984, 106, 7143-7145.
(19) Lindsey, J . S. A retrospective on the automation of laboratory
synthetic chemistry. Chemom. Intell. Lab. Inf. Manage. 1992,
17, 15-45.
(20) Kuwahara, M. K. S.; Sugawara, T.; Miyake, A. Synthetic studies
on condensed-azole derivatives. II. Application of a computer-
assisted automated synthesis apparatus for the synthesis of
N-substituted sulfamoylpropylthioimidazo[1,2-b]pyridazines.
Chem. Pharm. Bull. 1995, 43, 1511-1515.
(21) Chen, C.; Dagnino, R., J r.; De Souza, E. B.; Grigoriadis, D. E.;
Huang, C. Q.; Kim, K.-I.; Lui, Z.; Moran, T.; Webb, T. R.;
Whitten, J . P.; Xie, Y. F.; McCarthy, J . R. Design and synthesis
of a series of non-peptide high-affinity corticotropin-releasing
factor1 receptor antagonists. J . Med. Chem. 1996, 39, 4358-
4360.
(22) Chen, Y. L. Corticotropin releasing factor antagonists. World
Patent Appl. WO 95/33750, December 14, 1995.
(23) Courtemanche, G.; Gautier, C.; Gully, D.; Roger, P.; Valette, G.;
Wermuth, C. G. Derivatives of alkylamino thiazoles, their
preparation and pharmaceutical composition. European Patent
Appl., EP 0 576 350 A1, December 29, 1993.
(24) Chen, Y. L. Pyrrolopyrimidines as CRF antagonists. World
Patent Appl., WO 94/13676, J une 23, 1994.
(25) Chen, Y. L. Pyrazolopyrimidines as CRF antagonists. World
Patent Appl., WO 94/13677, J une 23, 1994.
(26) Bright, G. M. Amino-substituted pyrazoles having CRF antago-
nist activity. World Patent Appl., WO 94/13644, J une 23, 1994.
(27) Bright, G. M.; Welch, W. M. J . Substituted pyrazoles as CRF
antagonists. World Patent Appl., WO 94/13661, J une 23, 1994.
(28) Aldrich, P. E.; Arvanitis, A. G.; Cheeseman, R. S.; Chorvat, R.
J .; Christos, T. E.; Gilligan, P. J .; Grigoriadis, D. E.; Hodge, C.
N.; Krenitsky, P. J .; Scholfield, E. L.; Tam, S. W.; Wasserman,
Z. R. 1N-Alkyl-N-arylpyrimidinamines and derivatives thereof.
World Patent Appl., WO 95/10506, April 20, 1995.
(29) Lovenberg, T. W.; Grigoriadis, D. E.; Chalmers, D. T.; McCarthy,
J . R.; De Souza, E. B. Corticotropin-releasing factor receptors:
Inhibitors, subtypes, pharmacology, localization, and their role
in central nervous system function. Curr. Pharm. Des. 1995, 1,
305-316.
(30) Gallop, M. A.; Barrett, R. W.; Dower, W. J .; Fodor, S. P. A.;
Gordon, E. M. Applications of combinatorial technologies to drug
discovery. 1. Background and peptide combinatorial libraries.
J . Med. Chem. 1994, 37, 1233-1251.
(31) Gordon, E. M.; Barrett, R. W.; Dower, W. J .; Fodor, S. P. A.;
Gallop, M. A. Applications of Combinatorial Technologies to
Drug Discovery. 2. Combinatorial Organic Synthesis, Library
Screening Strategies, and Future Directions. J . Med. Chem.
1994, 37, 1385-1401.
(32) Bunin, B. A.; Ellman, J . A. A general and expedient method for
the solid-phase synthesis of 1,4-benzodiazepine derivatives. J .
Am. Chem. Soc. 1992, 114, 10997-10998.
(33) DeWitt, S. H.; Kiely, J . S.; Stankovic, C. J .; Schroeder, M. C.;
Reynolds-Cody, D. M.; Pavia, M. R. “Diversomers”: An approach
to nonpeptide, nonoligomeric chemical diversity. Proc. Natl.
Acad. Sci. U.S.A. 1993, 90, 6909-6913.
(34) Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis
of a tetrapeptide. J . Med. Chem. 1963, 85, 2149-2154.
(35) Fodor, S. P. A. R.; Pirrung, M. C.; Stryer, L.; Lu, A. T.; Solas, D.
Light-directed, spatially addressable parallel chemical synthesis.
Science 1991, 251, 767-773.
(36) Geysen, H. M. M.; Barteling, S. J . Use of peptide synthesis to
probe viral antigens for epitopes to a resolution of a single amino
acid. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3998-4002.
Su p p or tin g In for m a tion Ava ila ble: A description of
modifications to the original PrepStation, Figure 2, illustrating
capabilities/functions of the PrepStation, general experimental
procedures (sequential steps in the computer programs) for
the preparation of the triazines 5 and the cyclopropylmethy-
lamines 4 on the HP PrepStation, and a table with compounds,
CRF1 receptor binding data, parent ion as determined by GC
MS or M + 1 as determined by ion spray MS, amount of
material submitted for testing, % yield, and purity as esti-
mated by GC MS; in addition, an expansion of the introduction
to solution and solid phase robotics chemistry is included (54
pages). Ordering information is given on any current mast-
head page.
Refer en ces
(1) Chang, C. P.; Pearse, R. I.; O’Connell, S.; Rosenfeld, M. G.
Identification of a seven transmembrane helix receptor for
corticotropin-releasing factor and sauvagine in mammalian
brain. Neuron 1993, 11, 1187-1195.
(2) Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression
cloning of a human corticotropin-releasing-factor receptor. Proc.
Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971.
(3) Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J . M.; Kaghad,
M.; Le, F. G.; Caput, D.; Ferrara, P. Primary structure and
functional expression of mouse pituitary and human brain
corticotrophin releasing factor receptors. FEBS Lett. 1993, 335,
1-5.
(4) Perrin, M. H.; Donaldson, C. J .; Chen, R.; Lewis, K. A.; Vale,
W. W. Cloning and functional expression of a rat brain corti-
cotropin releasing factor (CRF) receptor. Endocrinology 1993,
133, 3058-3061.
(5) Chalmers, D. T.; Lovenberg, T. W.; De Souza, E. B. Localization
of novel corticotropin-releasing factor receptor (CRF2) mRNA
to specific sub-cortical nuclei in rat brain: Comparison with
CRF1 receptor mRNA expression. J . Neurosci. 1995, 15, 6340-
6350.
(6) Liaw, C. W.; Lovenberg, T. W.; Barry, G.; Oltersdorf, T.;
Grigoriadis, D. E.; De Souza, E. B. Cloning and characterization
of the human CRF2 receptor gene and cDNA. Endocrinology
1996, 137, 72-77.
(7) Lovenberg, T. W.; Liaw, C. W.; Grigoriadis, D. E.; Clevenger,
W.; Chalmers, D. T.; De Souza, E. B.; Oltersdorf, T. Cloning and
characterization of a functionally distinct corticotropin-releasing
factor receptor subtype from rat brain. Proc. Natl. Acad. Sci.
U.S.A. 1995, 92, 836-840.
(8) Lovenberg, T. W.; Chalmers, D. T.; Liu, C.; De Souza, E. B.
CRF2R and CRF2â receptor mRNAs are differentially distributed
between the rat central nervous system and peripheral tissues.
Endocrinology 1995, 136, 4139-4142.
(9) Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.;
Bilezikjian, L.; Sawchenko, P.; Vale, W. Identification of a second
corticotropin-releasing factor receptor gene and characterization
of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995,
92, 2969-2973.
(10) De Souza, E. B.; Lovenberg, T. W.; Chalmers, D. T.; Grigoriadis,
D. E.; Liaw, C. W.; Behan, D. P.; McCarthy, J . R. Heterogeneity
of corticotropin-releasing factor receptors: Multiple targets for
the treatment of CNS and inflammatory disorders. Annu. Rep.
Med. Chem. 1995, 30, 21-30.
(11) Nemeroff, C. B.; Owens, M. J .; Bissett, G.; Andorn, A. C.; Stanley,
M. Reduced corticotropin-releasing factor receptor binding sites
in the frontal cortex of suicide victims. Arch. Gen. Psych. 1988,
45, 577-579.